AIDS progression (any new WHO Stage 3 or 4 condition), virologic and CD4 cell response, HIV and TB drug resistance, and safety and tolerability of and adherence to HIV and TB drugs will be evaluated, as will the cost-effectiveness of the two strategies. This evidence concerns the gene CD4 and tuberculosis.